Principal Financial Group Inc. Raises Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Principal Financial Group Inc. lifted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 10.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 113,560 shares of the biotechnology company’s stock after buying an additional 10,909 shares during the period. Principal Financial Group Inc. owned approximately 0.07% of Heron Therapeutics worth $174,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC grew its position in Heron Therapeutics by 21.2% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 7,927 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Heron Therapeutics by 18.4% during the third quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 79,680 shares in the last quarter. King Wealth Management Group boosted its holdings in Heron Therapeutics by 52.3% during the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock worth $46,000 after buying an additional 8,000 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Heron Therapeutics during the third quarter worth $72,000. Finally, FMR LLC boosted its holdings in Heron Therapeutics by 26.2% during the third quarter. FMR LLC now owns 431,906 shares of the biotechnology company’s stock worth $859,000 after buying an additional 89,601 shares in the last quarter. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Up 1.3 %

HRTX opened at $2.39 on Friday. The company has a market cap of $364.07 million, a price-to-earnings ratio of -13.28 and a beta of 1.55. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The firm’s fifty day simple moving average is $1.77 and its two-hundred day simple moving average is $1.73.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million. On average, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on HRTX. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Needham & Company LLC reissued a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Friday, February 28th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.